Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
2004 1
2005 2
2006 4
2007 7
2008 16
2009 18
2010 52
2011 73
2012 115
2013 122
2014 153
2015 147
2016 118
2017 103
2018 90
2019 109
2020 91
2021 76
2022 9
2023 8
2024 30

Search Results

1,167 results

Results by year

Filters applied: . Clear all
Page 1
Improved survival with vemurafenib in melanoma with BRAF V600E mutation.
Chapman PB, Hauschild A, Robert C, Haanen JB, Ascierto P, Larkin J, Dummer R, Garbe C, Testori A, Maio M, Hogg D, Lorigan P, Lebbe C, Jouary T, Schadendorf D, Ribas A, O'Day SJ, Sosman JA, Kirkwood JM, Eggermont AM, Dreno B, Nolop K, Li J, Nelson B, Hou J, Lee RJ, Flaherty KT, McArthur GA; BRIM-3 Study Group. Chapman PB, et al. N Engl J Med. 2011 Jun 30;364(26):2507-16. doi: 10.1056/NEJMoa1103782. Epub 2011 Jun 5. N Engl J Med. 2011. PMID: 21639808 Free PMC article. Clinical Trial.
Combined BRAF, EGFR, and MEK Inhibition in Patients with BRAFV600E-Mutant Colorectal Cancer.
Corcoran RB, André T, Atreya CE, Schellens JHM, Yoshino T, Bendell JC, Hollebecque A, McRee AJ, Siena S, Middleton G, Muro K, Gordon MS, Tabernero J, Yaeger R, O'Dwyer PJ, Humblet Y, De Vos F, Jung AS, Brase JC, Jaeger S, Bettinger S, Mookerjee B, Rangwala F, Van Cutsem E. Corcoran RB, et al. Cancer Discov. 2018 Apr;8(4):428-443. doi: 10.1158/2159-8290.CD-17-1226. Epub 2018 Feb 5. Cancer Discov. 2018. PMID: 29431699 Free PMC article. Clinical Trial.
Mutant B-Raf Kinase Inhibitors as Anticancer Agents.
Asati V, Bharti SK, Mahapatra DK. Asati V, et al. Anticancer Agents Med Chem. 2016;16(12):1558-1575. doi: 10.2174/1871520616666160606101848. Anticancer Agents Med Chem. 2016. PMID: 27264268 Review.
B-Raf and the inhibitors: from bench to bedside.
Huang T, Karsy M, Zhuge J, Zhong M, Liu D. Huang T, et al. J Hematol Oncol. 2013 Apr 25;6:30. doi: 10.1186/1756-8722-6-30. J Hematol Oncol. 2013. PMID: 23617957 Free PMC article. Review.
Targeting the BRAF pathway in haematological diseases.
Rees MJ, Dickinson M, Paterson J, Ng TF, Grigg A, Moore J, Blombery P, Seymour JF. Rees MJ, et al. Intern Med J. 2023 May;53(5):845-849. doi: 10.1111/imj.16091. Intern Med J. 2023. PMID: 37222093 Review.
Targeted Therapy for Melanoma.
Wong DJ, Ribas A. Wong DJ, et al. Cancer Treat Res. 2016;167:251-62. doi: 10.1007/978-3-319-22539-5_10. Cancer Treat Res. 2016. PMID: 26601866 Review.
Vemurafenib.
Flaherty KT, Yasothan U, Kirkpatrick P. Flaherty KT, et al. Nat Rev Drug Discov. 2011 Oct 31;10(11):811-2. doi: 10.1038/nrd3579. Nat Rev Drug Discov. 2011. PMID: 22037033
1,167 results